Abstract Objective: To assess factors associated with emotional changes and Hyperactivity/Inattention (HI) motivated by COVID-19 quarantine in adolescents with immunocompromising diseases. Methods: A cross-sectional study included 343 adolescents with immunocompromising diseases and 108 healthy adolescents. Online questionnaires were answered including socio-demographic data and self-rated healthcare routine during COVID-19 quarantine and validated surveys: Strengths and Difficulties Questionnaire (SDQ), Pittsburgh Sleep Quality Index (PSQI), Pediatric Quality of Life Inventory 4.0 (PedsQL4.0). Results: The frequencies of abnormal emotional SDQ scores from adolescents with chronic diseases were similar to those of healthy subjects (110/343 [32%] vs. 38/108 [35%], p = 0.548), as well as abnormal hyperactivity/inattention SDQ scores (79/343 [23%] vs. 29/108 [27%], p = 0.417). Logistic regression analysis of independent variables associated with abnormal emotional scores from adolescents with chronic diseases showed: female sex (Odds Ratio [OR = 3.76]; 95% Confidence Interval (95% CI) 2.00–7.05; p < 0.001), poor sleep quality (OR = 2.05; 95% CI 1.08–3.88; p = 0.028) and intrafamilial violence during pandemic (OR = 2.17; 95% CI 1.12–4.19; p = 0.021) as independently associated with abnormal emotional scores, whereas total PedsQL score was inversely associated with abnormal emotional scores (OR = 0.95; 95% CI 0.93–0.96; p < 0.0001). Logistic regression analysis associated with abnormal HI scores from patients evidenced that total PedsQL score (OR = 0.97; 95% CI 0.95–0.99; p = 0.010], changes in medical appointments during the pandemic (OR = 0.39; 95% CI 0.19–0.79; p = 0.021), and reliable COVID-19 information (OR = 0.35; 95% CI 0.16–0.77; p = 0.026) remained inversely associated with abnormal HI scores. Conclusion: The present study showed emotional and HI disturbances in adolescents with chronic immunosuppressive diseases during the COVID-19 pandemic. It reinforces the need to promptly implement a longitudinal program to protect the mental health of adolescents with and without chronic illnesses during future pandemics. Objective HyperactivityInattention Hyperactivity Inattention (HI COVID19 COVID 19 COVID-1 Methods crosssectional cross sectional 34 10 sociodemographic socio demographic selfrated self rated surveys SDQ, , (SDQ) PSQI, PSQI (PSQI) 40 4 0 4. PedsQL4.0. PedsQL40 PedsQL4.0 . PedsQL4 (PedsQL4.0) Results 110/343 110343 110 (110/34 32% 32 [32% vs 38108 38 38/10 35%, 35 35% [35%] 0.548, 0548 0.548 548 0.548) hyperactivityinattention hyperactivity inattention 79/343 79343 79 (79/34 23% 23 [23% 29108 29 29/10 27%, 27 27% [27%] 0.417. 0417 0.417 417 0.417) Odds OR 3.76 376 3 76 3.76] 95 (95 2.00–7.05 200705 2 00 7 05 0.001, 0001 0.001 001 0.001) 2.05 205 1.08–3.88 108388 1 08 88 0.028 0028 028 2.17 217 17 1.12–4.19 112419 12 0.021 0021 021 0.95 095 0.93–0.96 093096 93 96 0.0001. 00001 0.0001 0.0001) 0.97 097 97 0.95–0.99 095099 99 0.010, 0010 0.010 010 0.010] 0.39 039 39 0.19–0.79 019079 0.021, 0.35 035 0.16–0.77 016077 16 77 0.026 0026 026 Conclusion pandemics COVID1 COVID- (SDQ (PSQI PedsQL4. (PedsQL4.0 110/34 11034 11 (110/3 [32 3810 38/1 [35% 054 0.54 54 79/34 7934 (79/3 [23 2910 29/1 [27% 041 0.41 41 3.7 37 9 (9 2.00–7.0 20070 000 0.00 2.0 20 1.08–3.8 10838 8 0.02 002 02 2.1 21 1.12–4.1 11241 0.9 09 0.93–0.9 09309 0000 0.000 0.95–0.9 09509 0.01 01 0.3 03 0.19–0.7 01907 0.16–0.7 01607 (PedsQL4. 110/3 1103 (110/ [3 381 38/ [35 0.5 5 79/3 793 (79/ [2 291 29/ [27 04 0.4 3. ( 2.00–7. 2007 0.0 2. 1.08–3. 1083 1.12–4. 1124 0. 0.93–0. 0930 0.95–0. 0950 0.19–0. 0190 0.16–0. 0160 (PedsQL4 110/ (110 [ 79/ (79 2.00–7 200 1.08–3 1.12–4 112 0.93–0 093 0.95–0 0.19–0 019 0.16–0 016 (PedsQL (11 (7 2.00– 1.08– 1.12– 0.93– 0.95– 0.19– 0.16– (1 2.00 1.08 1.12 0.93 0.19 0.16 1.0 1.1 0.1 1.

Abstract Objectives: To evaluate the inconsistency between clinical diagnosis of death and autopsy findings in adolescents with chronic diseases. Methods: A cross-sectional study including a sample of adolescents’ autopsies who died in a pediatric and adolescent tertiary hospital over 18 consecutive years. During this period, there were n = 2912 deaths, and n = 581/2912(20%) occurred in adolescents. Of these, n = 85/581(15%) underwent autopsies and were analyzed. Further results were divided into two groups: Goldman classes I or II (high disagreement between main clinical diagnosis of death and anatomopathological findings, n = 26) and Goldman classes III, IV or V (low or no disagreement between these two parameters, n = 59). Results: Median age at death (13.5 [10‒19] vs. 13 [10‒19] years, p = 0.495) and disease duration (22 [0‒164] vs. 20 [0‒200] months, p = 0.931), and frequencies for males (58% vs. 44%, p = 0.247) were similar between class I/II vs. class III/IV/V. The frequency of pneumonia (73% vs. 48%, p = 0.029), pulmonary abscess (12% vs. 0%, p = 0.026), as well as isolation of yeast (27% vs. 5%, p = 0.008), and virus (15% vs. 2%, p = 0.029) identified in the autopsy, were significantly higher in adolescents with Goldman class I/II compared to those with Goldman class III/IV/V. In contrast, cerebral edema was significantly lower in adolescents of the first group (4% vs. 25%, p = 0.018). Conclusion: This study showed that 30% of the adolescents with chronic diseases had major discrepancies between clinical diagnosis of death and autopsy findings. Pneumonia, pulmonary abscess, as well as isolation of yeast and virus were more frequently identified at autopsy findings in the groups with major discrepancies. Objectives Methods crosssectional cross sectional 1 years period 291 deaths 581/291220% 581291220 581/2912 20% 581 581/2912(20% 85/58115% 8558115 85/581 15% 85 15 85/581(15% analyzed high 26 III low parameters 59. 59 . 59) Results 13.5 135 5 (13. 10‒19 1019 10 19 [10‒19 vs 0.495 0495 0 495 22 (2 0‒164 0164 164 [0‒164 2 0‒200 0200 200 [0‒200 months 0.931, 0931 0.931 , 931 0.931) 58% 58 (58 44 44% 0.247 0247 247 IIIIVV III/IV/V 73% 73 (73 48 48% 0.029, 0029 0.029 029 12% 12 (12 0% 0.026, 0026 0.026 026 0.026) 27% 27 (27 5% 0.008, 0008 0.008 008 0.008) (15 2% contrast 4% 4 (4 25 25% 0.018. 0018 0.018 018 0.018) Conclusion 30 Pneumonia 29 291220 581/291220 58129122 5812912 581/291 581/2912(20 58115 85/58115 855811 85581 85/58 8 85/581(15 13. (13 10‒1 101 [10‒1 0.49 049 49 ( 0‒16 016 16 [0‒16 0‒20 020 [0‒20 093 0.93 93 (5 0.24 024 24 7 (7 002 0.02 02 (1 000 0.00 00 001 0.01 01 3 29122 581/29122 581291 581/29 581/2912(2 5811 85/5811 8558 85/5 85/581(1 10‒ [10‒ 0.4 04 0‒1 [0‒1 0‒2 [0‒2 09 0.9 9 0.2 0.0 58129 581/2 581/2912( 855 85/ 85/581( [10 0. 0‒ [0‒ 5812 581/ [1 [0 [

RESUMO A toxocaríase é uma zoonose parasitária causada principalmente pelo Toxocara canis ou peloT. cati. É adquirida pela ingestão de ovos embrionados do parasita. A artralgia e/ou artriteforam relatadas em até 17% dos casos, geralmente com duração aguda (menos de seis sema-nas). No entanto, que se tem conhecimento, a poliartrite crônica como manifestação isoladada infecção por Toxocara ainda não foi descrita na literatura. Um dos 5.809 pacientes acom-panhados em nosso serviço (0,017%) exibiu poliartrite crônica como manifestação únicada toxocaríase e foi descrito neste estudo. Uma menina de três anos foi encaminhada aonosso serviço com poliartrite crônica dolorosa grave por um período superior a 10 semanase rigidez matinal diária de 30 minutos. Foi relatada história de exposição a contato comcão nas áreas de lazer do bairro. Seus exames revelaram níveis elevados de eosinófilos nosangue periférico (29%), o aspirado de medula óssea revelou eosinofilia acentuada (32%)e o ensaio imunoenzimático ligado a enzima (ELISA) para Toxocara foi positivo (1:1.280). Acriança foi tratada com paracetamol (40 mg/kg/dia) e tiabendazol (25 mg/kg/dia) durante10 dias e houve regressão de todas as manifestações. Depois de oito meses de seguimento,a pequena paciente estava em remissão clínica e laboratorial. Em conclusão, descreve-seum caso de poliartrite crônica como manifestação isolada da toxocaríase, que mimetizouuma artrite idiopática juvenil e leucemia. É importante ressaltar que essa zoonose deve serconsiderada em pacientes com artrite e eosinofilia.

ABSTRACT Human toxocariasis is a parasitic zoonosis mainly caused by Toxocara canis or Toxocara catiand is acquired by ingestion of the parasite’s embryonated eggs. Arthralgia and/or arthri-tis were reported in up to 17% of the cases, generally with acute duration (less than 6weeks). However, to our knowledge, chronic polyarthritis, as the isolated presentation ofToxocara infection, was not reported. One of the 5809 patients that was followed up at ourservice (0.017%) had chronic polyarthritis as the single manifestation of toxocariasis and wasdescribed herein. A 3-year-old girl was referred to our service with severe painful chronicpolyarthritis for a period longer than 10 weeks and morning stiffness of 30 min. Dog contactexposure history in the recreational areas of neighborhood was reported. Her exams showedhigh levels of eosinophils in peripheral blood (29%), bone marrow aspirate revealed markedeosinophilia (32%) and Toxocara enzyme-linked immunosorbent assay (Elisa) was positive(1:1280). She was treated with paracetamol (40 mg/kg/day) and thiabendazole (25 mg/kg/day)for 10 days, and all manifestations reduced. After eight months of follow-up, she was onclinical and laboratorial remission. In conclusion, we described a case of chronic polyarthri-tis, as isolated manifestation of toxocariasis, mimicking juvenile idiopathic arthritis andleukemia. Importantly, this zoonosis should be considered in patients with arthritis andeosinophilia.

Resumo Introdução Ictiose arlequim é uma doença cutânea congênita grave, autossômica e rara, caracterizada por ressecamento excessivo da pele e hiperqueratose. A associação de ictiose com esclerose sistêmica foi descrita em apenas três crianças. Ainda não foi descrito nenhum paciente com morfeia generalizada (MG) associada à ictiose arlequim. Relato de caso: Menina de quatro anos e seis meses de idade com diagnóstico de ictiose arlequim baseado em espessamento cutâneo difuso, com fissuras, descamação, eritema e sangramento da lesão desde as primeiras horas de vida. A paciente foi tratada com acitretina (1,0 mg/kg/dia) e creme emoliente. Aos três anos e nove meses, desenvolveu contraturas musculares com dor à movimentação e limitação nos cotovelos e joelhos e placas esclerodérmicas difusas no abdômen, nas costas, na região suprapúbica e nas extremidades inferiores. A biópsia de pele mostrou epiderme retificada e hiperqueratose leve, derme reticular com linfócitos, infiltrado mononuclear perivascular e perianexial e esclerose da derme reticular e glândula sudorípara rodeada por um tecido colágeno denso, compatível com esclerodermia. A paciente preencheu os critérios para o subtipo MG. Metotrexato e prednisona foram introduzidos. Aos quatro anos e três meses, apresentou novas lesões esclerodérmicas, associando-se azatioprina à terapêutica anterior, sem resposta após dois meses. Discussão: Um caso de ictiose arlequim associada à MG foi descrito. O tratamento dessas duas condições é um desafio e requer uma equipe multidisciplinar.

Abstract Introduction: Harlequin ichthyosis (HI) is a severe and rare hereditary congenital skin disorder characterized by excessive dryness, ectropion and eclabion. The association of ichthyosis with systemic sclerosis has been described in only three children. No patient with generalized morphea (GM) associated with harlequin ichthyosis was described. Case report: A 4-years and 6-months girl, diagnosed with harlequin ichthyosis based on diffuse cutaneous thickening, scaling, erythema, ectropion and eclabium since the first hours of birth was described. She was treated with acitretin (1.0 mg/kg/day) and emollient cream. At 3 years and 9 months, she developed muscle contractures with pain on motion and limitation in elbows and knees, and diffuse sclerodermic plaques on the abdomen, back, suprapubic area and lower limbs. Skin biopsy showed rectified epidermis and mild hyperorthokeratosis, reticular dermis with perivascular and periadnexal infiltrates of lymphocytes and mononuclear cells, and reticular dermis and sweat gland sclerosis surrounded by a dense collagen tissue, compatible with scleroderma. The patient fulfilled the GM subtype criteria. Methotrexate and prednisone were introduced. At 4 years and 3 months, new scleroderma lesions occurred and azathioprine was associated with previous therapy, with no apparent changes after two months. Discussion: A case of harlequin ichthyosis associated with a GM was reported. The treatment of these two conditions is a challenge and requires a multidisciplinary team.